Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cellectis

- PMLiVE

AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly

German media reports suggested vaccine is less than 10% effective in the elderly

- PMLiVE

AstraZeneca reduces initial COVID-19 vaccine deliveries to the EU

Deliveries in the first quarter have been cut by 60%

- PMLiVE

Real-world evidence: breaking boundaries in rare disease

Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Blue Latitude Health

- PMLiVE

The heavy toll of COVID-19 on cancer patients

We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Blue Latitude Health

- PMLiVE

Unpacking rare diseases in the first edition of Delta magazine

Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization

Blue Latitude Health

- PMLiVE

Trial combining British and Russian COVID-19 vaccines could begin in February

AstraZeneca announced the clinical trial programme in December

- PMLiVE

Lilly partners with Merus on development of bispecific antibodies for cancer

As part of the deal, Merus could receive a total of up to around $1.6bn for three products

- PMLiVE

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours

Investigational PD-1 inhibitor is being studied in mismatch repair-deficient solid tumours

- PMLiVE

Live Webinar: COVID-19 Has Changed Live Events Forever!

We invite you to join Impetus Digital and the Medical Affairs Professional Society (MAPS) on February 19, 10 am EST, for a thought-provoking webinar around the future of virtual events.

Impetus Digital

- PMLiVE

New dosing option for AZ’s Imfinzi approved in the EU and UK

Additional option extends dosing from two weeks to four weeks

- PMLiVE

AstraZeneca’s focus on diagnosing and managing chronic kidney disease

People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care

- PMLiVE

AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine

CHMP could reach a decision on opinion by 29 January

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links